Compare IDEXX Laboratories, Inc. (IDXX) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Levi Strauss & Co. — how do they compare? IDEXX Laboratories, Inc. trades at $571.7 (market cap $46.22B), while Levi Strauss & Co. trades at $22.57 (market cap $8.75B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.3× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LEVI | |
|---|---|---|
Market Cap | $46.22B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $25.53 |
52-Week Low | $526.44 | $17.92 |
Enterprise Value | $47.12B | $10.07B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Levi Strauss & Co. (LEVI) trades at $23.59, down 3.32% over 24 hours, amid a recent cybersecurity incident disclosed on August 7, 2026. The stock shows strong fundamentals with a P/E of 16.24, robust gross margin of 61.72%, and consistent earnings beats in recent quarters. Technical indicators are bearish, with support near $23, while analyst consensus remains bullish with a $27.88 price target.
The outlook for LEVI is positive due to solid DTC growth and raised 2026 guidance, but risks include cybersecurity concerns and tariff pressures. Earnings momentum and a reasonable valuation support upside potential, though near-term volatility may persist from the security breach and market reactions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
